FDA clears Masimo's noninvasive sensors for haemoglobin and oxygen
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for Masimo's latest family of Rainbow adhesive sensors for noninvasive monitoring of haemoglobin and oxygen. The sensors are for use with the firm's Rainbow SET-enabled devices, and can also measure oxygen saturation, pulse rate, Pleth variability index (which determines patients' fluid levels) and methaemoglobin. Irvine, California-based Masimo has also launched its noninvasive Radical-7 and Rad-87 continuous haemoglobin and oxygen monitors on a limited basis, to "selected hospitals around the world". The noninvasive test was cleared by the FDA in May (see Clinica No 1307, p 22). Previously, measuring haemoglobin involved taking a blood sample and sending it to the laboratory for testing.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.